Adviser Investments LLC Buys New Stake in Thermo Fisher Scientific Inc. (TMO)

Share on StockTwits

Adviser Investments LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 1st quarter, Holdings Channel reports. The firm bought 3,573 shares of the medical research company’s stock, valued at approximately $978,000.

Several other institutional investors have also modified their holdings of TMO. Oregon Public Employees Retirement Fund boosted its position in shares of Thermo Fisher Scientific by 44,296.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 19,521,889 shares in the last quarter. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $946,280,000. FMR LLC boosted its position in shares of Thermo Fisher Scientific by 33.4% during the 4th quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock valued at $1,940,642,000 after acquiring an additional 2,172,574 shares in the last quarter. BlackRock Inc. lifted its holdings in Thermo Fisher Scientific by 3.7% during the 4th quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock valued at $5,858,214,000 after purchasing an additional 944,035 shares during the last quarter. Finally, Cantillon Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 91.3% during the 4th quarter. Cantillon Capital Management LLC now owns 1,024,930 shares of the medical research company’s stock valued at $229,369,000 after purchasing an additional 489,081 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Shares of NYSE TMO opened at $271.80 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $202.83 and a 1-year high of $282.98. The stock has a market capitalization of $108.71 billion, a price-to-earnings ratio of 24.44, a P/E/G ratio of 1.74 and a beta of 1.11. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.07. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The company had revenue of $6.13 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the previous year, the firm posted $2.50 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.2 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Shareholders of record on Friday, June 14th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Thursday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.

Several equities analysts recently issued reports on TMO shares. UBS Group lifted their price target on shares of Thermo Fisher Scientific to $305.00 and gave the company a “buy” rating in a report on Monday, March 25th. BTIG Research lifted their price target on shares of Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a report on Thursday. Barclays lifted their price target on shares of Thermo Fisher Scientific from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Bank of America reissued a “buy” rating and set a $300.00 price target (up from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Finally, Deutsche Bank lifted their price target on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $295.92.

In related news, insider Gregory J. Herrema sold 3,299 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $263.05, for a total transaction of $867,801.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 50,713 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the sale, the chief executive officer now directly owns 302,193 shares of the company’s stock, valued at $82,562,149.53. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,512 shares of company stock valued at $15,388,101. Insiders own 0.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4353764/adviser-investments-llc-buys-new-stake-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report